Capture FDA Regulatory Sovereignty via SBIR Phase II Dependency
- Organization
- NSF SBIR Phase I program funding medical device R&D without providing regulatory clearance infrastructure
- Sector
- DELEON TECHNOLOGIES principals desperate for FDA pathway to secure Phase II funding
- Location
- Newark, DE / Atlanta, GA
Source reference
Executive summary
Current state
NSF awarded DELEON TECHNOLOGIES $305K SBIR Phase I funding to develop a disposable microfluidic chip for urine analysis, creating a classic "SBIR Valley of Death" scenario where government-funded technical capability exists without commercial infrastructure for FDA clearance, manufacturing scale, or data monetization.
Market catalyst
DELEON TECHNOLOGIES has $305K NSF SBIR Phase I funding for medical device R&D but zero FDA regulatory pathway expertise or infrastructure - they must navigate 510(k) clearance for Phase II success but lack the specialized knowledge and institutional relationships required
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.